BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23527324)

  • 1. The role of imatinib in the treatment of pulmonary hypertension.
    Mucke H
    Drugs Today (Barc); 2013 Mar; 49(3):203-11. PubMed ID: 23527324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment with imatinib for refractory PAH].
    Nakamura K; Akagi S; Sarashina T; Ogawa A; Matsubara H; Ito H
    Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):173-7. PubMed ID: 24717604
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib mesylate for the treatment of pulmonary arterial hypertension.
    ten Freyhaus H; Dumitrescu D; Berghausen E; Vantler M; Caglayan E; Rosenkranz S
    Expert Opin Investig Drugs; 2012 Jan; 21(1):119-34. PubMed ID: 22074410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1α depletion or imatinib treatment.
    Veith C; Zakrzewicz D; Dahal BK; Bálint Z; Murmann K; Wygrecka M; Seeger W; Schermuly RT; Weissmann N; Kwapiszewska G
    Thromb Haemost; 2014 Dec; 112(6):1288-303. PubMed ID: 25231004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.
    Perros F; Montani D; Dorfmüller P; Durand-Gasselin I; Tcherakian C; Le Pavec J; Mazmanian M; Fadel E; Mussot S; Mercier O; Hervé P; Emilie D; Eddahibi S; Simonneau G; Souza R; Humbert M
    Am J Respir Crit Care Med; 2008 Jul; 178(1):81-8. PubMed ID: 18420966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib].
    Nishida T; Tsukazaki K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():250-5. PubMed ID: 25831762
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.
    Koon HB; Krown SE; Lee JY; Honda K; Rapisuwon S; Wang Z; Aboulafia D; Reid EG; Rudek MA; Dezube BJ; Noy A
    J Clin Oncol; 2014 Feb; 32(5):402-8. PubMed ID: 24378417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAR-2 inhibition reverses experimental pulmonary hypertension.
    Kwapiszewska G; Markart P; Dahal BK; Kojonazarov B; Marsh LM; Schermuly RT; Taube C; Meinhardt A; Ghofrani HA; Steinhoff M; Seeger W; Preissner KT; Olschewski A; Weissmann N; Wygrecka M
    Circ Res; 2012 Apr; 110(9):1179-91. PubMed ID: 22461388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension.
    Chhina MK; Nargues W; Grant GM; Nathan SD
    Future Cardiol; 2010 Jan; 6(1):19-35. PubMed ID: 20014985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
    Godinas L; Guignabert C; Seferian A; Perros F; Bergot E; Sibille Y; Humbert M; Montani D
    Semin Respir Crit Care Med; 2013 Oct; 34(5):714-24. PubMed ID: 24037637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Imatinib for pulmonary arterial hypertension].
    Hoeper MM; Opitz C; Olschewski H; Ulrich S; Speich R; Behr J; Halank M; Wilkens H; Klose H; Lange TJ; Grünig E; Seeger W; Ewert R; Borst MM; Welte T; Rosenkranz S; Ghofrani HA
    Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S151-4. PubMed ID: 25489685
    [No Abstract]   [Full Text] [Related]  

  • 12. Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension.
    Nakamura K; Akagi S; Ogawa A; Kusano KF; Matsubara H; Miura D; Fuke S; Nishii N; Nagase S; Kohno K; Morita H; Oto T; Yamanaka R; Otsuka F; Miura A; Yutani C; Ohe T; Ito H
    Int J Cardiol; 2012 Aug; 159(2):100-6. PubMed ID: 21376411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension.
    Hatano M; Yao A; Shiga T; Kinugawa K; Hirata Y; Nagai R
    Int Heart J; 2010 Jul; 51(4):272-6. PubMed ID: 20716845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
    Jasińska-Stroschein M; Owczarek J; Plichta P; Orszulak-Michalak D
    Pharmacology; 2014; 93(3-4):145-50. PubMed ID: 24662671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.
    De Pas T; Toffalorio F; Colombo P; Trifirò G; Pelosi G; Vigna PD; Manzotti M; Agostini M; de Braud F
    J Thorac Oncol; 2008 Aug; 3(8):938-41. PubMed ID: 18670317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.
    Hoeper MM; Barst RJ; Bourge RC; Feldman J; Frost AE; Galié N; Gómez-Sánchez MA; Grimminger F; Grünig E; Hassoun PM; Morrell NW; Peacock AJ; Satoh T; Simonneau G; Tapson VF; Torres F; Lawrence D; Quinn DA; Ghofrani HA
    Circulation; 2013 Mar; 127(10):1128-38. PubMed ID: 23403476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib as rescue therapy in a patient with pulmonary hypertension associated with Gaucher disease.
    Al-Naamani N; Roberts KE; Hill NS; Preston IR
    Chest; 2014 Sep; 146(3):e81-e83. PubMed ID: 25180747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension.
    Gambaryan N; Perros F; Montani D; Cohen-Kaminsky S; Mazmanian GM; Humbert M
    Eur Respir J; 2010 Nov; 36(5):1209-11. PubMed ID: 21037371
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
    Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A lymphocyte-dependent mode of action for imatinib mesylate in experimental pulmonary hypertension.
    Ormiston ML; Deng Y; Rundle N; Bendjelloul F; Tsoporis JN; Parker TG; Stewart DJ; Courtman DW
    Am J Pathol; 2013 May; 182(5):1541-51. PubMed ID: 23518411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.